Travere Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Travere Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Travere Therapeutics Inc Strategy Report
- Understand Travere Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3611 Valley Centre Dr, Suite 300, San Diego, California, 92130
Website
travere.com
Telephone
1 760 2608600
No of Employees
380
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TVTX (NASD)
Revenue (2022)
$145.2M
32.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
60%
(2022 vs 2021)
Market Cap*
$441.4M
Net Profit Margin (2022)
XYZ
69.9%
(2022 vs 2021)
* As of and is in US$
Travere Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Thiola |
| Tiopronin for the treatment of cystinuria | Cholbam |
| Cholic Acid for pediatric and adult patients with bile acid synthesis disorders | Chenodal |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Asset Disposal | In September, the company sold its bile acid product portfolio to Mirum Pharmaceuticals. |
| 2023 | Regulatory Approval | In February, the company secured approval from FDA for FILSPARI(sparsentan), the First and Only Non-immunosuppressive Therapy for the treatment of Reduction of Proteinuria in IgA Nephropathy. |
| 2022 | Regulatory Approval | In May, the company secured approval from USFDA for Sparsentan for the Treatment of IgA Nephropathy. |
Competitor Comparison
| Key Parameters | Travere Therapeutics Inc | AbbVie Inc | SciClone Pharmaceuticals Holdings Ltd | Intercept Pharmaceuticals Inc | Voyager Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | China | United States of America | United States of America |
| City | San Diego | North Chicago | Shanghai | Morristown | Lexington |
| State/Province | California | Illinois | Shanghai | New Jersey | Massachusetts |
| No. of Employees | 380 | 50,000 | 1,050 | 341 | 162 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gary A. Lyons | Chairman | Executive Board | 2016 | 71 |
| Eric Dube, Ph.D. | Chief Executive Officer; President; Director | Executive Board | 2019 | 50 |
| Chris Cline | Chief Financial Officer; Senior Vice President - Investor Relations & Corporate Communications | Senior Management | - | - |
| Jula Inrig, M.D | Chief Medical Officer | Senior Management | 2022 | 48 |
| Peter Heerma | Chief Commercial Officer | Senior Management | 2019 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward